Which antihypertensive medications are safe and recommended for use during pregnancy?

Safe Antihypertensive Medications in Pregnancy

For pregnant women with hypertension, first-line oral medications are labetalol, methyldopa, and long-acting nifedipine, while ACE inhibitors and ARBs are absolutely contraindicated due to fetal renal toxicity. 1

First-Line Oral Agents (Grade C Evidence)

The following medications have the strongest safety and efficacy data for chronic hypertension management during pregnancy:

• Labetalol (β-blocker with α1-blocking activity)
• Methyldopa (central α2-agonist)
• Long-acting nifedipine (calcium channel blocker)
• Other β-blockers: acebutolol, metoprolol, pindolol, propranolol 1

Recent network meta-analysis data suggests labetalol may have a modest advantage over nifedipine for reducing preeclampsia (RR 0.50) and preterm birth (RR 0.68), though overall quality of evidence remains low-to-moderate. 2 Nifedipine demonstrates superior efficacy in preventing persistent severe hypertension compared to both hydralazine (RR 0.40) and labetalol (RR 0.71). 3

Practical Selection Strategy:

• Start with nifedipine for once-daily dosing and better adherence, particularly effective for preventing severe hypertension
• Switch to labetalol if patient experiences headaches, tachycardia, or edema from nifedipine, or add as combination therapy
• Avoid labetalol in patients with reactive airway disease (asthma)
• Consider methyldopa in resource-limited settings where it may be the only available option, though it has fallen out of favor in high-income countries 4

Second-Line Oral Agents (Grade D Evidence)

When first-line monotherapy fails to achieve target BP, add agents from different classes 1:

• Clonidine
• Hydralazine
• Thiazide diuretics (can be continued if already on therapy for chronic hypertension, but not routinely initiated)

Treatment Thresholds and Targets

Initiate antihypertensive therapy when BP ≥140/90 mmHg in pregnant women with chronic hypertension, gestational hypertension, or preeclampsia. 1

Target diastolic BP of 85 mmHg (Grade B evidence), with systolic BP maintained between 110-140 mmHg. 1, 5 Reduce or discontinue medications if diastolic BP falls below 80 mmHg. 5

Severe Hypertension/Hypertensive Emergency

BP ≥160/110 mmHg requires urgent treatment within 15 minutes as this constitutes an obstetrical emergency. 1, 6, 5

Acute Management Options:

• IV labetalol (10-20 mg bolus, titrate 20-80 mg every 10-30 minutes, max 300 mg) 6
• Oral nifedipine immediate-release (10-20 mg, can repeat) - though associated with risk of uncontrolled hypotension, especially with concurrent magnesium sulfate 6
• IV hydralazine (5 mg bolus, titrate 5-10 mg every 20 minutes, max 30 mg) - now less preferred due to more perinatal adverse effects 7, 6

Critical caveat: Avoid sublingual nifedipine due to unpredictable absorption and risk of precipitous hypotension. 8 Do not combine oral nifedipine with magnesium sulfate without close monitoring due to synergistic hypotensive effects. 6

Absolutely Contraindicated Medications (Grade C Evidence)

ACE inhibitors and ARBs must not be used in pregnancy - they cause fetal renal toxicity, oligohydramnios, and are teratogenic in second and third trimesters. 1, 9, 10

Also contraindicated:

• Direct renin inhibitors 9, 10
• Atenolol (associated with fetal growth restriction) 8
• Mineralocorticoid receptor antagonists 4

Discontinue ACE inhibitors and ARBs in women planning pregnancy (Grade D recommendation). 1

Postpartum and Lactation

Safe medications during breastfeeding (Grade D evidence) 1:

• Labetalol
• Methyldopa
• Long-acting nifedipine
• Enalapril
• Captopril

Avoid methyldopa postpartum due to risk of postnatal depression. 7 ACE inhibitors (enalapril, captopril) become acceptable options after delivery for breastfeeding mothers despite being contraindicated during pregnancy. 1

Key Clinical Pitfalls

1. Do not use short-acting nifedipine for chronic management - reserve only for acute severe hypertension
2. Labetalol may require TID or QID dosing during pregnancy due to accelerated drug metabolism 4
3. BP typically worsens postpartum days 3-6 - maintain vigilance and treatment 8
4. Hypertension from HDPs should resolve by 12 weeks postpartum - persistent elevation warrants chronic hypertension workup 4
5. Sodium nitroprusside is last-resort only for extreme emergencies due to fetal cyanide toxicity risk 7, 6